These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8488850)

  • 1. Cardiovascular remodeling and its correction: toward a comprehensive strategy.
    Bühler FR; Laragh JH; Holzgreve H
    Am J Med; 1993 Apr; 94(4A):1S-3S. PubMed ID: 8488850
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of cilazapril, a converting enzyme inhibitor, on cardiovascular hypertrophy in the hypertensive patient].
    Sesin J; Tamargo J
    Medicina (B Aires); 1996; 56(1):75-84. PubMed ID: 8734937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of the selective blocking of angiotensin II receptors in the treatment of cardiovascular diseases].
    Carnovali M
    Clin Ter; 2001; 152(2):103-6. PubMed ID: 11441521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Resistance to ACE inhibitors. Myth or reality?].
    Aumont MC; Juliard JM
    Arch Mal Coeur Vaiss; 2001 Sep; 94(9):1008-12. PubMed ID: 11603063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factor-induced cardiovascular remodeling and the effects of angiotensin-converting enzyme inhibitors.
    Galderisi M; de Divitiis O
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):523-31. PubMed ID: 18520954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
    Ferrari R
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical pharmacology of angiotensin II receptor antagonists].
    Hitzenberger G
    Wien Med Wochenschr; 2001; 151(7-8):151-2. PubMed ID: 11450161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the role of angiotensin-receptor blockade in cardiovascular protection?
    Cohn JN
    Am Heart J; 2006 Nov; 152(5):859.e1-8. PubMed ID: 17070145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin receptor blockers and cardiovascular protection: are we ONTARGET?
    Ram CV; Deedwania PC
    Am J Cardiol; 2008 Nov; 102(9):1281-3. PubMed ID: 18940307
    [No Abstract]   [Full Text] [Related]  

  • 10. [Angiotensin II antagonist receptors].
    Tamargo J
    Med Clin (Barc); 2000; 114 Suppl 1():6-13. PubMed ID: 10812568
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of ACE-I on diabetic cardiovascular complications: anti-hypertensive and non-antihypertensive doses.
    Udayachalerm W; Vechakarn O; Patumraj S
    J Med Assoc Thai; 2001 Jun; 84 Suppl 1():S306-13. PubMed ID: 11529349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme and vascular remodeling.
    Heeneman S; Sluimer JC; Daemen MJ
    Circ Res; 2007 Aug; 101(5):441-54. PubMed ID: 17761934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future directions in cardiovascular pharmacology: examples from the Renin-Angiotensin system.
    Diz DI
    Mol Interv; 2008 Oct; 8(5):222-5. PubMed ID: 19015385
    [No Abstract]   [Full Text] [Related]  

  • 14. Evolving role of angiotensin-converting enzyme inhibitors in cardiovascular therapy. Second International Symposium on Cilazapril. February 9 to 11, 1989, Basel, Switzerland. Proceedings.
    Am J Med; 1989 Dec; 87(6B):1S-99S. PubMed ID: 2532456
    [No Abstract]   [Full Text] [Related]  

  • 15. Characteristics of the effects of the angiotensin converting enzyme inhibitor cilazapril on diurnal blood pressure.
    Nakanishi T; Takahashi H; Nishimura M; Yoshimura M
    Clin Ther; 1993; 15(2):294-303. PubMed ID: 8519038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiology patient page. What is an angiotensin converting enzyme inhibitor?
    Sweitzer NK
    Circulation; 2003 Jul; 108(3):e16-8. PubMed ID: 12876137
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical efficacy of losartan: are there any differences between angiotensin II type I receptor antagonists and other drugs?].
    Redon J; Ferrario CM
    Med Clin (Barc); 2000; 114 Suppl 1():23-8. PubMed ID: 10812571
    [No Abstract]   [Full Text] [Related]  

  • 18. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA
    Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial dysfunction and the promise of ACE inhibitors.
    Rockett JL
    Am J Nurs; 1999 Oct; 99(10):44-9; quiz 50. PubMed ID: 10542849
    [No Abstract]   [Full Text] [Related]  

  • 20. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.